Carisbamate

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Carisbamate
DrugBank Accession Number
DB12338
Background

Carisbamate has been investigated in Alcohol Abuse, Substance Abuse, and Alcohol Dependence.

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 215.63
Monoisotopic: 215.0349209
Chemical Formula
C9H10ClNO3
Synonyms
  • Carisbamate
External IDs
  • JNJ-10234094
  • RWJ-333369-000
  • YKP-509

Pharmacology

Indication

Not Available

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
1,2-BenzodiazepineThe risk or severity of adverse effects can be increased when Carisbamate is combined with 1,2-Benzodiazepine.
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Carisbamate.
AcetophenazineThe risk or severity of adverse effects can be increased when Acetophenazine is combined with Carisbamate.
AclidiniumCarisbamate may increase the central nervous system depressant (CNS depressant) activities of Aclidinium.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Carisbamate.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Carisbamate.
AlimemazineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Carisbamate.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Carisbamate.
AlosetronThe risk or severity of adverse effects can be increased when Alosetron is combined with Carisbamate.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Carisbamate.
Interactions
Improve patient outcomes
Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.
Learn more
Food Interactions
Not Available

Categories

ATC Codes
N03AX19 — Carisbamate
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as chlorobenzenes. These are compounds containing one or more chlorine atoms attached to a benzene moiety.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Halobenzenes
Direct Parent
Chlorobenzenes
Alternative Parents
Aryl chlorides / Carbamate esters / Secondary alcohols / Organonitrogen compounds / Organochlorides / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds / Aromatic alcohols
Substituents
Alcohol / Aromatic alcohol / Aromatic homomonocyclic compound / Aryl chloride / Aryl halide / Carbamic acid ester / Carbonyl group / Chlorobenzene / Hydrocarbon derivative / Organic nitrogen compound
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
P7725I9V3Z
CAS number
194085-75-1
InChI Key
OLBWFRRUHYQABZ-MRVPVSSYSA-N
InChI
InChI=1S/C9H10ClNO3/c10-7-4-2-1-3-6(7)8(12)5-14-9(11)13/h1-4,8,12H,5H2,(H2,11,13)/t8-/m1/s1
IUPAC Name
(2S)-2-(2-chlorophenyl)-2-hydroxyethyl carbamate
SMILES
NC(=O)OC[C@@H](O)C1=CC=CC=C1Cl

References

General References
Not Available
PubChem Compound
6918474
PubChem Substance
347828597
ChemSpider
5293671
ChEBI
135966
ChEMBL
CHEMBL2087003
ZINC
ZINC000030691363
Wikipedia
Carisbamate

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentComplex Partial Seizures / Epilepsies / Epilepsy, Complex Partial / Epilepsy, Localization Related1
3CompletedTreatmentEpilepsy, Complex Partial / Epilepsy, Partial, Motor / Epilepsy, Simple Partial / Focal Motor Epilepsy2
3TerminatedTreatmentEpilepsies / Seizures1
2CompletedTreatmentDiabetic Mononeuropathy / Diabetic Neuropathy, Painful / Diabetic Polyneuropathy / Neuralgia, Diabetic1
2CompletedTreatmentDiabetic Neuropathies1
2CompletedTreatmentEssential Tremor, Movement Disorders1
2CompletedTreatmentHerpes Zoster / Neuralgia / Postherpetic Neuralgia1
1Active Not RecruitingTreatmentHealthy Volunteers1
1RecruitingBasic ScienceLennox Gastaut Syndrome / Lennox-Gastaut Syndrome (LGS)2
1, 2CompletedOtherAlcohol Abuse / Alcohol Dependency / Substance Abuse1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility2.15 mg/mLALOGPS
logP0.94ALOGPS
logP1.29ChemAxon
logS-2ALOGPS
pKa (Strongest Acidic)13.43ChemAxon
pKa (Strongest Basic)-3.5ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area72.55 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity51.47 m3·mol-1ChemAxon
Polarizability20.38 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on October 20, 2016 22:00 / Updated on February 21, 2021 18:53